5.1M XNAS Volume
XNAS 17 Apr, 2025 5:30 PM (EDT)
Ardelyx Inc Key Metrics
Select
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
10Positive11Negative
47.6% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Ardelyx Inc Stock Price Analysis
Day Price Range | 4.8 (LTP) 4.64.8 LowHigh |
Week Price Range | 4.8 (LTP) 4.44.8 LowHigh |
Month Price Range | 4.8 (LTP) 45.6 LowHigh |
52 Week Price Range | 4.8 (LTP) 49.3 LowHigh |
Ardelyx Inc Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Consensus Recommendation
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Ardelyx Inc Stock Analysis
Ardelyx Inc stock analysis with key metrics, changes, and trends.
Ardelyx Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $333.62 M | 168.06% | positive |
| |
Annual Net Profit | $39.14 M | 40.76% | positive |
| |
Price to Earning Ratio | -29.36 | - | negative |
| |
Stock Price | $4.82 | -25.62% | negative |
| |
Quarterly Revenue | $116.13 M | 237.95% | positive |
| |
Quarterly Net profit | $4.64 M | 116.13% | positive |
| |
Debt to Equity Ratio | 0.89 | - | positive |
| |
Return on Equity(ROE) | -23.01 % | -23.01% | negative |
| |
Mutual Fund Holding | 47.28 % | -0.36% | negative |
| |
Promoter Share Holding | 10.96 % | 1.65% | positive |
| |
Interest Coverage Ratio | -0.93 | - | negative |
| |
Institutional Holding | 63.37 % | 0.02% | positive |
|
Loading data..
Ardelyx Inc - Company Profile
What does Ardelyx Inc do?
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx Inc Management structure
All Gross Remunerations are in USD
Ardelyx Inc Board of directors
All Gross Remunerations are in USD